January 24, 2006; 66 (2) Brief Communications
Creatine in Huntington disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2′dG
S. M. Hersch, S. Gevorkian, K. Marder, C. Moskowitz, A. Feigin, M. Cox, P. Como, C. Zimmerman, M. Lin, L. Zhang, A. M. Ulug, M. F. Beal, W. Matson, M. Bogdanov, E. Ebbel, A. Zaleta, Y. Kaneko, B. Jenkins, N. Hevelone, H. Zhang, H. Yu, D. Schoenfeld, R. Ferrante, H. D. Rosas
First published January 24, 2006, DOI: https://doi.org/10.1212/01.wnl.0000194318.74946.b6
S. M. Hersch
S. Gevorkian
K. Marder
C. Moskowitz
A. Feigin
M. Cox
P. Como
C. Zimmerman
M. Lin
L. Zhang
A. M. Ulug
M. F. Beal
W. Matson
M. Bogdanov
E. Ebbel
A. Zaleta
Y. Kaneko
B. Jenkins
N. Hevelone
H. Zhang
H. Yu
D. Schoenfeld
R. Ferrante
Creatine in Huntington disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2′dG
S. M. Hersch, S. Gevorkian, K. Marder, C. Moskowitz, A. Feigin, M. Cox, P. Como, C. Zimmerman, M. Lin, L. Zhang, A. M. Ulug, M. F. Beal, W. Matson, M. Bogdanov, E. Ebbel, A. Zaleta, Y. Kaneko, B. Jenkins, N. Hevelone, H. Zhang, H. Yu, D. Schoenfeld, R. Ferrante, H. D. Rosas
Neurology Jan 2006, 66 (2) 250-252; DOI: 10.1212/01.wnl.0000194318.74946.b6
Citation Manager Formats
Make Comment
See Comments

Article Information
vol. 66 no. 2 250-252
PubMed:
Print ISSN:
Online ISSN:
History:
- First Published January 24, 2006.
Copyright & Usage:
© 2006
Author Disclosures
- S. M. Hersch, MD, PhD,
- S. Gevorkian, MSc,
- K. Marder, MD, MPH,
- C. Moskowitz, MS,
- A. Feigin, MD,
- M. Cox, MS, RN,
- P. Como, PhD,
- C. Zimmerman, RN,
- M. Lin, MD,
- L. Zhang, MD,
- A. M. Ulug, PhD,
- M. F. Beal, MD,
- W. Matson, PhD,
- M. Bogdanov,
- E. Ebbel,
- A. Zaleta, BA,
- Y. Kaneko, BA,
- B. Jenkins, PhD,
- N. Hevelone, MPH,
- H. Zhang, MS,
- H. Yu, MPH,
- D. Schoenfeld, PhD,
- R. Ferrante, PhD, MSc and
- H. D. Rosas, MD, MS
- S. M. Hersch, MD, PhD,
- S. Gevorkian, MSc,
- K. Marder, MD, MPH,
- C. Moskowitz, MS,
- A. Feigin, MD,
- M. Cox, MS, RN,
- P. Como, PhD,
- C. Zimmerman, RN,
- M. Lin, MD,
- L. Zhang, MD,
- A. M. Ulug, PhD,
- M. F. Beal, MD,
- W. Matson, PhD,
- M. Bogdanov,
- E. Ebbel,
- A. Zaleta, BA,
- Y. Kaneko, BA,
- B. Jenkins, PhD,
- N. Hevelone, MPH,
- H. Zhang, MS,
- H. Yu, MPH,
- D. Schoenfeld, PhD,
- R. Ferrante, PhD, MSc and
- H. D. Rosas, MD, MS
- From the Departments of Neurology, (S.M.H., S.G., A.Z., N.H., H.Z., H.Y., H.D.R.) and Biostatistics (D.S.), MassGeneral Institute for Neurodegenerative Disease, MGH-NMR Center and Athinoula A. Martinos Center for Biomedical Imaging (A.Z., B.J., N.H., H.D.R.), Massachusetts General Hospital and Harvard Medical School, Charlestown, MA; Center for Parkinson's Disease and Other Movement Disorders (K.M., C.M.), Department of Neurology, Sergievsky Center and Taub Institute for Research on Alzheimer's Disease and the Aging Brain (K.M.), Columbia University, New York, NY; Center for Neuroscience, Institute for Medical Research (A.F., M.C.), North Shore-LIJ Health System, Manhasset, NY; Department of Neurology (P.C., C.Z.), University of Rochester, Rochester, NY; Departments of Neurology and Neuroscience (M.L., M.F.B., M.B.), and Radiology (L.Z., A.M.U.), Weill Medical College of Cornell University, New York, NY; Edith Nourse Veterans Administration Medical Center (W.M., M.B., E.E., R.F.), Geriatric Research and Education and Clinical Center, Bedford, MA; Departments of Neurology, Pathology, and Psychiatry (R.F.) and Biochemistry (W.M., R.F.), Boston University School of Medicine, Boston, MA.
- Address correspondence and reprint requests to Dr. Steven Hersch, MassGeneral Institute for Neurodegenerative Disease, MGH East Building 114-2001, 114 16th Street, Charlestown, MA 02129; e-mail: hersch{at}helix.mgh.harvard.edu.
Article usage
Cited By...
Letters: Rapid online correspondence
No comments have been published for this article.
REQUIREMENTS
If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Advertisement
Dr. Jeffrey Allen and Dr. Nicholas Purcell
► Watch
Alert Me
Recommended articles
-
Article
Clinical manifestations of intermediate allele carriers in Huntington diseaseEsther Cubo, María A. Ramos-Arroyo, Saul Martinez-Horta et al.Neurology, July 08, 2016 -
Articles
Ethyl-EPA in Huntington diseaseA double-blind, randomized, placebo-controlled trialB. K. Puri, B. R. Leavitt, M. R. Hayden et al.Neurology, July 25, 2005 -
Articles
Tetrabenazine as antichorea therapy in Huntington diseaseA randomized controlled trialHuntington Study Group et al.Neurology, February 13, 2006 -
Articles
Safety and tolerability of the free-radical scavenger OPC-14117 in Huntington's diseaseThe Huntington Study Group* et al.Neurology, May 01, 1998